• Users Online: 848
  • Print this page
  • Email this page
Year : 2020  |  Volume : 11  |  Issue : 4  |  Page : 482-492

What is new in the pathogenesis and management of erythema nodosum leprosum

Department of Dermatology, Father Muller Medical College, Mangalore, Karnataka, India

Correspondence Address:
Ramesh M Bhat
Department of Dermatology, Father Muller Medical College, Kankanady, Mangalore - 575 002, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/idoj.IDOJ_561_19

Rights and Permissions

Erythema nodosum leprosum (ENL) is a manifestation of type II lepra reaction, seen in lepromatous or borderline lepromatous leprosy. Although it is a common reaction encountered in clinical practice, there are an increasingly large number of newer updates in the pathophysiology and management of this condition.The treatment options have expanded far beyond just thalidomide and steroids and now extends to TNF-α inhibitors, thalidomide analogs, tenidap, cyclosporine A, plasma exchange, and even IVIG amongst others. These updates and the current knowledge of ENL are summarized in this review.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded678    
    Comments [Add]    
    Cited by others 2    

Recommend this journal